Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftriaxone Sodium

FDA-approved product (injectable, injection), marketed as Ceftriaxone, Ceftriaxone And Dextrose In Duplex Container, Ceftriaxone In Plastic Container and 3 more.

Registered studies
50+
Lab records
68
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ceftriaxone Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Gonorrhea
  • Infection
  • Infectious meningitis
  • Otitis media
  • Pelvic Inflammatory Disease
  • Respiratory tract infectious disorder
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD04; WHO ATC J01DD54

Repurposing investigation

Ceftriaxone Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA82.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 8 of 8 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 26 of 56 lab records
Open Ceftriaxone Sodium in ChEMBL Registered studies below
Show the 68 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftriaxone Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients

    NCT05417997 · start 2021-05-29

    Registered record
    Registry ID
    NCT05417997
    Conditions
    COVID-19 Respiratory Infection; FLU; Cold; Influenza; Bacterial Pneumonia; COVID-19 Pneumonia
    Interventions
    Kunamin®; Favipiravir; Enoxaparin; Lansoprazole; Paracetamol; Ceftriaxone/ Clarithromycin; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-29
    Completion
    2021-12-02
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Respiratory Infection; FLU; Cold; Influenza +2 more
    InterventionKunamin®; Favipiravir; Enoxaparin; Lansoprazole +3 more
    PhasePhase 3
    Registry statusCompleted

  • Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea

    NCT06090565 · start 2021-04-01

    Registered record
    Registry ID
    NCT06090565
    Conditions
    Gonorrhea
    Interventions
    Cefixime; Doxycyclin; Ceftriaxon; Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2022-12-22
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhea
    InterventionCefixime; Doxycyclin; Ceftriaxon; Azithromycin
    PhasePhase 4
    Registry statusCompleted

  • Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

    NCT04574596 · start 2020-11-12

    Registered record
    Registry ID
    NCT04574596
    Conditions
    E Coli Infection
    Interventions
    no Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-12
    Completion
    2021-06-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionE Coli Infection
    Interventionno Intervention
    PhaseNot recorded
    Registry statusCompleted

  • EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA

    NCT04347512 · start 2020-06-02

    Registered record
    Registry ID
    NCT04347512
    Conditions
    Sars-CoV-2, Community-Acquired Pneumonia,COVID-19
    Interventions
    Hydroxychloroquine and azithromycin treatment arm.; Hydroxychloroquine; Control arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-06-02
    Completion
    2020-06-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSars-CoV-2, Community-Acquired Pneumonia,COVID-19
    InterventionHydroxychloroquine and azithromycin treatment arm.; Hydroxychloroquine; Control arm
    PhasePhase 3
    Registry statusWithdrawn

  • Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

    NCT03915366 · start 2020-03-01

    Registered record
    Registry ID
    NCT03915366
    Conditions
    Pneumonia; HIV/AIDS; Tuberculosis; Cytomegalovirus Infections
    Interventions
    Valganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-03-01
    Completion
    2025-01-31
    Enrolment
    563

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; HIV/AIDS; Tuberculosis; Cytomegalovirus Infections
    InterventionValganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years

    NCT03583749 · start 2019-08-07

    Registered record
    Registry ID
    NCT03583749
    Conditions
    Antimicrobials; Subcutaneous Injection; Antibiotic; Older People
    Interventions
    Subcutaneous (SC) route for antibiotic treatment; Intravenous (IV) route for antibiotic treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-08-07
    Completion
    2021-09-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntimicrobials; Subcutaneous Injection; Antibiotic; Older People
    InterventionSubcutaneous (SC) route for antibiotic treatment; Intravenous (IV) route for antibiotic treatment
    PhaseNot recorded
    Registry statusUnknown

  • 2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Control Acute Gastroesophageal Variceal Hemorrhage

    NCT04056806 · start 2019-08

    Registered record
    Registry ID
    NCT04056806
    Conditions
    Variceal Rebleeding Rate and Infections
    Interventions
    Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-08
    Completion
    2022-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVariceal Rebleeding Rate and Infections
    InterventionTerlipressin 1Mg Powder for Conventional Release Solution for Injection Vial
    PhasePhase 4
    Registry statusUnknown

  • Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)

    NCT03922919 · start 2018-04-03

    Registered record
    Registry ID
    NCT03922919
    Conditions
    Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)
    Interventions
    Cefotaxime Injection; Rectal swab; Cefotaxime/ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-04-03
    Completion
    2020-10
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfectious Disease - Resistant Enterobacteriaceae (Diagnosis)
    InterventionCefotaxime Injection; Rectal swab; Cefotaxime/ceftriaxone
    PhasePhase 4
    Registry statusUnknown

  • Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units

    NCT03440216 · start 2018-03-15

    Registered record
    Registry ID
    NCT03440216
    Conditions
    Pharmacokinetics; Anti-Bacterial Agents; Infection, Bacterial; Infections, Respiratory; Infection; Drug Monitoring
    Interventions
    blood sampling; Tissue sampling (lung); Collection of fluid samples
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-03-15
    Completion
    2022-12-15
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Anti-Bacterial Agents; Infection, Bacterial; Infections, Respiratory +2 more
    Interventionblood sampling; Tissue sampling (lung); Collection of fluid samples
    PhaseNot applicable
    Registry statusUnknown

  • Risk Factors and Common Preventive Measures for Ventilator Associated Pneumonia in Patients With Severe Traumatic Brain Injury

    NCT03266380 · start 2018-01-01

    Registered record
    Registry ID
    NCT03266380
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    observational
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2019-12-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    Interventionobservational
    PhaseNot recorded
    Registry statusUnknown

  • Appendectomy Versus Conservative Treatment for Uncomplicated Acute Appendicitis

    NCT03080103 · start 2017-06-01

    Registered record
    Registry ID
    NCT03080103
    Conditions
    Acute Appendicitis; Appendicitis Recurrent; Appendectomy; Antibiotic Therapy
    Interventions
    Laparoscopic or Open appendectomy; Antibiotic-first therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2019-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis; Appendicitis Recurrent; Appendectomy; Antibiotic Therapy
    InterventionLaparoscopic or Open appendectomy; Antibiotic-first therapy
    PhaseNot recorded
    Registry statusCompleted

  • Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

    NCT03289351 · start 2017-05-22

    Registered record
    Registry ID
    NCT03289351
    Conditions
    Perforated Appendicitis; Postoperative Infection
    Interventions
    Piperacillin, Tazobactam Drug Combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-22
    Completion
    2023-11-07
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerforated Appendicitis; Postoperative Infection
    InterventionPiperacillin, Tazobactam Drug Combination
    PhasePhase 4
    Registry statusCompleted

  • Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients

    NCT02389036 · start 2017-05-01

    Registered record
    Registry ID
    NCT02389036
    Conditions
    Critical Illness; Sepsis; Septic Shock; Ventilator Associated Pneumonia
    Interventions
    SDD Oral Paste; SDD Gastric Suspension; Intravenous Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2023-04-26
    Enrolment
    20,010

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Sepsis; Septic Shock; Ventilator Associated Pneumonia
    InterventionSDD Oral Paste; SDD Gastric Suspension; Intravenous Antibiotic
    PhasePhase 3
    Registry statusCompleted

  • Experimental Human Infection With Neisseria Gonorrhoeae

    NCT03840811 · start 2017-04-23

    Registered record
    Registry ID
    NCT03840811
    Conditions
    Gonococcal Infection
    Interventions
    Cefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26; Neisseria gonorrhoeae strain FA7537
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-23
    Completion
    2019-11-25
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonococcal Infection
    InterventionCefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26 +1 more
    PhasePhase 1
    Registry statusCompleted

  • Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery

    NCT02996656 · start 2016-12

    Registered record
    Registry ID
    NCT02996656
    Conditions
    Propionibacterium Infection
    Interventions
    Cefazolin; Ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2016-12
    Completion
    2026-12
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPropionibacterium Infection
    InterventionCefazolin; Ceftriaxone
    PhaseNot applicable
    Registry statusRecruiting